Skip to main content
Cyber Week Sale - Get 40% off Vantage
Published loading...Updated

Theravance Biopharma, Inc. (TBPH) Stock Analysis: Exploring A 35% Upside Potential In Biotechnology

Summary
Theravance Biopharma, Inc. (NASDAQ: TBPH) presents an intriguing opportunity for savvy investors with its promising potential upside of 35.01%, as indicated by the average target price of $24.17 against its current price of $17.90. Operating within the dynamic biotechnology sector, Theravance’s strategic focus on developing and commercializing novel therapeutics positions it well for future growth. #### Company Snapshot Theravance Biopharma, bas…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.Cross Cancel Icon

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

DirectorsTalk Interviews broke the news in on Friday, November 21, 2025.
Too Big Arrow Icon
Sources are mostly out of (0)
News
Feed Dots Icon
For You
Search Icon
Search
Blindspot LogoBlindspotLocal